Effect of ayurvedic drug Divya Trighan in patients with increased uric acid.
Phase 3
Recruiting
- Conditions
- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease. Ayurveda Condition: VATARAKTAM,
- Registration Number
- CTRI/2023/07/055433
- Lead Sponsor
- Patanjali Research Institute governed by Patanjali Research Foundation Trust
- Brief Summary
This study is a single arm,open-label, prospective, observational study.Participants will be enroled for 6 months.The primary outcome includes improvement in laboratory parameters after 2 months of interventions. Secondary outcomes include assessment of quality of life of the patient
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- The subject with raised uric acid level in blood or urine (male: ≥ 8.5 mg/dl and female ≥ 7.3mg/dl) 2.
- Males or Females of age limit 18 to 60 years.
- Patient agrees to provide informed consent.
- Patient willing to participate in the study and ready to comply with study protocols.
- No alcohol or drug dependency.
Exclusion Criteria
- Pregnancy or lactation, intent to become pregnant.
- The subject with complications of pre-existing comorbidities or surgical intervention or undergone dialysis in last 3 month.
- The subject with known history of uncontrolled DM and HTN.
- The subject not willing to provide consent.
- The subject not willing to comply with the protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the change in Uric acid levels after treatment with Divya Trighan in patients with Hyperuricemia. Baseline, 4 weeks, 8 weeks
- Secondary Outcome Measures
Name Time Method •Change in the Quality of life of patients with SF-36 questionnaire day 1,day 30,day 60
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of Divya Trighan may influence uric acid metabolism in VATARAKTAM patients?
How does Divya Trighan compare to standard-of-care treatments like allopurinol in hyperuricemia management?
Are there specific biomarkers that could predict patient response to Divya Trighan in CTRI/2023/07/055433?
What are the potential adverse events associated with Divya Trighan in managing hyperuricemia?
What are the current combination therapies or competitor drugs for Ayurvedic treatment of VATARAKTAM?
Trial Locations
- Locations (1)
Patanjali Wellness Center
🇮🇳Hardwar, UTTARANCHAL, India
Patanjali Wellness Center🇮🇳Hardwar, UTTARANCHAL, IndiaDr Anurag SharmaPrincipal investigator8700567087clinical.investigator@patanjali.res.in